The Antisense Pharma Team

Hubert Heinrichs is Chief Medical Officer at Antisense Pharma since 2006. Additionally he served as chief executive officer from Jul-2011 until Feb-2012. He has over 20 years of pharmaceutical industry experience. Prior to joining Antisense Pharma, he was responsible at Aventis Behring for the worldwide coordination of all clinical studies from Phase I to IV and also for the clinical part of dossiers of five approved innovative medications in Europe and the USA. He received his medical degree from the Eberhard Karls University in Tübingen, Germany. He is specialized in immunology with 3 years of post-doctoral research fellowship at the Department of Human Genetics, University of Minnesota, USA, and held appointments at the Max-Planck Institute for Immunology in Tübingen, Germany, as well as the Institute for Immunology in Basel, Switzerland. He earned his M.B.A. at the Aston Business School in Birmingham, UK.

Richardis Hörmann is responsible for pharmacovigilance at Antisense Pharma since 2010. She has more than 20 years of pharmaceutical industry experience. Prior to joining Antisense Pharma, she worked as Pharmacovigilance Manager at Betapharm (A Dr. Reddy’s Company). Before that, she was employed at Hoffmann-La Roche, Novartis, and Bristol-Myers Squibb, both at their headquarters in Switzerland as well as in affiliates in Germany and Great Britain. She gained expert knowledge in pharmacovigilance, and is also familiar with regulatory affairs. Her broad experience in pharmacovigilance covers all drug safety-relevant activities up to preparing and actively participating in pharmacovigilance inspections. A particular challenge in her professional career was her active involvement in the establishment of a Global Center for Drug Safety for Roche in Great Britain. She is a biologist with a focus on biochemistry and microbiology and received her M.Sc. at the University of Hohenheim, Germany.

Ulrich Kiskalt is Head of Human Resources and Administration at Antisense Pharma since 2011. He has about 25 years of experience in personnel management. Before joining Antisense Pharma, he successfully managed several leadership- and employee-development projects as well as general HR-projects at the Munich International Airport. He focused primarily on human resources strategy, personnel management and executive development. He has also worked as a corporate coach, specializing in human resources and project management and as lecturer at the University of Applied Sciences in Regensburg, Germany. He began his career as an officer in the German Federal Armed Forces inter alia at the United Nations as well as the NATO. He holds a degree in Business Administration (Dipl.-Betriebswirt (FH)) from the University of the German Federal Armed Forces (Universität der Bundeswehr) in Munich, Germany.

Klaus R. Lindner is Head of Manufacturing and Qualified Person and responsible for the pharmaceutical development of trabedersen at Antisense Pharma since 2001. He has more than 30 years of pharmaceutical industry experience with more than 10 years of working in the field of oligonucleotides. Before joining Antisense Pharma, he served as Director of Drug Discovery at the Bristol-Myers Squibb Research Center in Regensburg, Germany. He studied chemistry, received his M.Sc. from the University of Pretoria, South Africa, and his Ph.D. from the Federal Institute of Technology in Zurich, Switzerland (ETH Zürich) in the laboratory of Prof. Dr. Albert Eschenmoser. After completing his Ph.D., he joined the group of Prof. Dr. Rolf Huisgen at the University of Munich, Germany as a postdoctoral research associate for 1½ years.

Andreas Terjung is Head of Regulatory Affairs at Antisense Pharma since 2007. He has almost 20 years of pharmaceutical industry experience. Prior to joining Antisense Pharma, he was responsible for the global regulatory management of various drug projects in respiratory indications at Byk Gulden/Altana Pharma (now Nycomed) – initially as Regulatory Manager and shortly thereafter as Head of Regulatory Affairs. Before that, he held various positions at the company - first in medical chemistry and then in clinical research gastroenterology. Parallel to these responsibilities, he was also Project Leader for the global management of drug projects in this indication. He has extensive experience in interacting with regulatory authorities, mainly in the EU, North America, but also in Asian countries. He has a M.Sc. in Chemistry and a Ph.D. in Organic Chemistry from the University of Konstanz, Germany. He also holds a M.Sc. in Regulatory Affairs from the University of Cardiff, U.K.

Hermann Werle is Head of Finance and Controlling at Antisense Pharma since 2009. He has more than 20 years of health care industry experience. Prior to joining Antisense Pharma, he worked for Tyco Healthcare (now Covidien) and Gerresheimer Wilden. He had served as Controller, Head of Administration, Proxy, General Manager Finance, General Manager Commercial, Commercial Manager International and Human Resources Manager International. In these functions, he gained experience in due diligence, acquisition, restructuring, operational and legal integration/merger of companies over the course of 9 company-acquisitions (e.g. Mallinckrodt, Sherwood Davis & Geck, U.S.-Surgical). He was responsible for strategic planning, finance and controlling, IT, purchasing, legal, warehouse and distribution. He holds a Degree in Business Administration from the University of Applied Sciences in Regensburg, Germany.